For example, the CDK9 inhibitor alvocidib showed encouraging clinical results for refractory AML through the MCL-1-dependent pathway, while several CDK 4/6 inhibitors are under development to downregulate the FLT3 and KMT2A genes in AML. The gene discussed is CDK9; the disease is acute myeloid leukemia.